e-therapeutics raises £22.5m in share placing
Posted on May 14, 2021 by Jonathan Symcox
Listed biotechnology firm e-therapeutics has raised £22.5 million in a conditional share placing.
The Newcastle University spin-out last year expanded into RNA interference as a therapeutic modality to pursue drug discovery outcomes.
Former long-time CEO of Silence Therapeutics and former professional chess player Ali Mortazavi is credited with a successful reorganisation of the business last year.
He became CEO and chairman in October but stepped down from the latter position recently as the roles were split.
Professor Trevor Jones, a non-executive director at the firm since 2015, became the new chair.
Last year Mortazavi oversaw a raise of £11.6m growth funding to expand its platform capabilities, asset pipeline, team and relocate its head office in Oxford – where it is now based – and open a new London base.